You are here: Industry Insights > Imfinzi

News List

Imfinzi Approved in China for Small Cell Lung Cancer americanpharmaceuticalreview
July 20, 2021
AstraZeneca’s Imfinzi (durvalumab) has been approved in China for the 1st-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with standard of care platinum chemotherapy (etoposide plus a choice of ...
Imfinzi increases five year survival to 43 percent in Stage III lung cancer trial europeanpharmaceuticalreview
June 09, 2021
New data shows AstraZeneca’s Imfinzi (durvalumab) achieved an unprecedented five year survival rate of over 40 percent in patients with Stage III non-small cell lung cancer.
Imfinzi Demonstrates Unprecedented Survival in Lung Cancer americanpharmaceuticalreview
June 08, 2021
The PACIFIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a sustained, clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit at five years in patients with unresectable ...
AstraZeneca’s Imfinzi and Tremelimumab with Chemotherapy Demonstrated Overall Survival Benefit in Trial for Non-Small Cell Lung Cancer americanpharmaceuticalreview
May 08, 2021
The POSEIDON trial was a Phase III trial of AstraZeneca’s Imfinzi (durvalumab) plus platinum-based chemotherapy or Imfinzi, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) ...
AZ withdraws Imfinzi indication in the US for advanced bladder cancer pharmatimes
February 23, 2021
AstraZeneca (AZ) has announced the voluntary withdrawal of its immunotherapy Imfinzi in its advanced bladder cancer indication in the US.
Imfinzi Trial Does Not Meet Primary Endpoint americanpharmaceuticalreview
February 10, 2021
The KESTREL Phase III trial for AstraZeneca’s Imfinzi (durvalumab) did not meet the primary endpoint of improving overall survival (OS) versus the EXTREME treatment regimen (chemotherapy plus cetuximab), a standard of care ...
AZ’s Imfinzi fails to improve overall survival in head and neck cancer again pharmatimes
February 09, 2021
AstraZeneca’s Imfinzi has failed to improved overall survival (OS) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) for the second time.
Imfinzi approved in the EU for less-frequent, fixed-dose use in unresectable non-small cell lung cancer pharmaceutical-business-review
January 20, 2021
New option extends dosing from two to four weeks, reducing medical visits and improving patient convenience.
Imfinzi Approved in US for Less-Frequent, Fixed-Dose Use americanpharmaceuticalreview
December 08, 2020
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy ..
FDA approves new dosing option for AZ’s Imfinzi pharmatimes
November 25, 2020
The US Food and Drug Administration (FDA) has approved AstraZeneca’s (AZ) checkpoint inhibitor Imfinzi for an additional dosing option.

Previous page 1 2 3 4 5 Next page